Humira access in Pakistan

How patients in Pakistan reach reference Humira (adalimumab) across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and uveitis, via the DRAP Personal Use Import NOC.

Quick orientation

Humira (adalimumab) is AbbVie's TNF-alpha inhibitor and was the first fully human monoclonal antibody ever approved by the FDA, originally cleared in December 2002 for moderately to severely active rheumatoid arthritis. The label has expanded to cover RA, psoriatic arthritis, ankylosing spondylitis, Crohn's disease (adult and pediatric six years and older), ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, polyarticular JIA (two years and older), and non-infectious intermediate, posterior, and panuveitis. Pakistan has a particularly significant adalimumab biosimilar demand picture, with multiple Indian and global biosimilars in the local market through DRAP listings, yet sustained named-patient demand for reference Humira persists. The Drug Regulatory Authority of Pakistan (DRAP) issues a Special Permission, also called the No Objection Certificate (NOC) for Personal Use Import, through its Online Import and Export System (OIES). **Reserved for you.**

Why patients in Pakistan need Humira via the named-patient pathway

Humira is one of the most broadly registered biologics globally, including in Pakistan through AbbVie's regional affiliate and authorized distributors. Multiple adalimumab biosimilars are also available in Pakistan: Indian biosimilars (Exemptia from Zydus Cadila, Adfrar from Torrent, others) are widely used regionally, and global FDA-approved biosimilars (Amjevita from Amgen, Abrilada from Pfizer, Cyltezo from Boehringer Ingelheim, Hadlima from Organon and Samsung Bioepis, Hyrimoz from Sandoz, Yusimry from Coherus, Hulio from Biocon and Viatris, and Simlandi from Alvotech and Teva) have entered global supply chains since 2023. Pakistan's adalimumab biosimilar demand profile is significant, with cost-sensitive families and public-sector institutions often defaulting to biosimilars. Yet three patterns continue to drive named-patient demand for reference Humira specifically.

First, local supply gaps during shortage windows. When a local agent's stock of a specific Humira SKU runs short (pen vs. syringe, citrate-free 100 mg/mL vs. citrate-containing 50 mg/mL), patients on continuous therapy cannot interrupt dosing without disease flare risk. Cross-border named-patient supply bridges the gap. Second, biosimilar substitution that the patient or treating physician declines. In Pakistan, public-sector procurement and some private payers default to a specific locally registered biosimilar. Patients who have stabilized on reference Humira and whose treating physician documents a clinical rationale for non-substitution may pursue cross-border supply of the specific named product. Third, cash-pay preference for product choice. Affluent self-pay patients who want a specific product (reference Humira, or a specific FDA-approved biosimilar not registered locally in Pakistan) use the named-patient pathway as the legal mechanism. In all three patterns the legal frame is the DRAP Personal Use Import NOC, and the prescriber's documented clinical rationale governs.

The DRAP named-patient pathway for Humira

DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing (QA and LT) Division's Import and Export Section. The Humira pathway is the Special Permission, also called the No Objection Certificate (NOC) for Personal Use Import, filed through DRAP's Online Import and Export System (OIES). The application package typically includes the treating physician's clinical justification letter, the physician's PMDC license verification, patient identifier (CNIC, B-Form for minors, or passport), product details with the specific SKU (40 mg/0.4 mL or 40 mg/0.8 mL prefilled pen or syringe; 80 mg loading dose options; 20 mg or 10 mg pediatric strengths; citrate-containing or citrate-free formulation as specified), the dispensing facility license, a manufacturer or authorized distributor letter from AbbVie's channel, and the chain-of-custody plan including cold-chain handling at 2 to 8 degrees Celsius.

The cell-specific clinical justification angle DRAP reviewers expect for a Humira case is a clear product-choice rationale combined with the indication-specific clinical picture. Where biosimilars are locally available, the letter should address why reference Humira (or a specific other FDA-approved biosimilar) is being specified rather than the locally registered biosimilar option. Common documented reasons include the patient having stabilized on the reference product over multiple years, the prescribing specialist not approving an inter-class switch, prior intolerance to a specific biosimilar formulation, or product-specific tolerability data. **Tuberculosis screening is mandatory before initiating Humira**, given Pakistan's high TB burden and the TNF-alpha class's known association with TB reactivation. The letter must document an interferon-gamma release assay (IGRA) or tuberculin skin test result, hepatitis B virus screening, and a plan to treat any latent TB before starting therapy. Routine personal-use cases typically clear in four to eight weeks; complex IBD cases extend to ten to sixteen weeks.

Where Humira gets dispensed in Pakistan

Humira requires institutions with validated cold-chain biologic storage at 2 to 8 degrees Celsius. The Humira label permits a single excursion to room temperature up to 25 degrees Celsius for up to 14 days, providing meaningful operational flexibility for the Karachi seaport or Karachi, Lahore, or Islamabad airport handoff lanes, but once removed to room temperature for that period the product cannot return to refrigeration. Aga Khan University Hospital in Karachi operates 24/7 temperature-controlled pharmacy storage with rheumatology, gastroenterology, dermatology, and ophthalmology services. Shifa International Hospital in Islamabad has an established import-pharmacy workflow with rheumatology and IBD capacity. Liaquat National Hospital and Indus Hospital and Health Network in Karachi both handle Humira cases through their tertiary services. Shaukat Khanum in Lahore handles cases for patients with concurrent oncology comorbidities. PKLI in Lahore handles gastroenterology and hepatology cases. CMH Rawalpindi and CMH Lahore in the Combined Military Hospitals network serve military families and civilian referrals. The Children's Hospital and Institute of Child Health in Lahore handles pediatric Crohn's, JIA, and uveitis cases requiring weight-banded dosing.

Subcutaneous prefilled pen and prefilled syringe presentations can be dispensed through the hospital outpatient pharmacy after cold-chain handoff. For physicians at smaller institutions, partnering with a DRAP-licensed specialty importer based in Karachi or Lahore handles the OIES filing, FBR customs clearance, and the chain-of-custody documentation while the patient's regular treating physician retains clinical oversight.

Real cost picture for Humira in Pakistan

Reference Humira US wholesale acquisition cost (WAC) sits at approximately USD 6,900 per monthly supply (40 mg every-other-week dosing, two 40 mg doses per month). On an annualized basis this is approximately USD 80,000 to USD 90,000 per year for the most common adult RA, psoriasis, or AS regimen at pre-biosimilar reference pricing. Biosimilar WACs vary widely: Hadlima launched at roughly 85 percent below reference Humira WAC; Amjevita used a dual-WAC strategy with one option 55 percent below Humira and another five percent below; Cyltezo and several others priced at modest five to seven percent discounts to retain rebate-driven formulary access. International payer pricing is country-specific and generally well below US WAC; published EU and MENA tender prices typically run 30 to 60 percent below US WAC for the reference product, and local Indian biosimilars in the Pakistan market sit substantially below either reference point.

For Pakistani cash-pay patients sourcing reference Humira via named-patient pathway, the cost stack includes reference Humira WAC drug cost, validated cold-chain international logistics typically in the USD 400 to USD 1,500 band per shipment, regulatory documentation handling, and the Reserve Meds concierge fee. Reserve Meds quotes in USD because Pakistan's annual CPI inflation reached 10.9 percent in April 2026 and the rupee has been volatile (USD to PKR 278.67 on 8 May 2026, 278 to 280 band early May). We accept wires from any USD-accessible source, important when families pool funds from relatives in Saudi Arabia, the UAE, the UK, the US, and Canada.

Typical timeline for Humira in Pakistan

The DRAP routine range of four to eight weeks applies to a complete first submission. Cold-chain biologics add two to three days at the US end relative to ambient drugs for thermal packout, temperature-logger placement, and bonded air-freight booking. The 14-day room-temperature excursion allowance gives meaningful operational flexibility through FBR customs at Karachi seaport or Karachi, Lahore, or Islamabad airports, but chain-of-custody discipline still favors lanes where the cold chain stays unbroken end-to-end. Plan on four to eight weeks for routine adult cases, six to ten weeks for pediatric weight-banded Crohn's or JIA cases where DRAP may ask for additional clinical clarification, and shorter resupply cycles once the case is on file with both DRAP and Reserve Meds.

What your physician needs to provide

The clinical justification letter is the cornerstone of the DRAP package. For Humira the letter should name the indication (RA, PsA, AS, Crohn's adult or pediatric, UC, plaque psoriasis, hidradenitis suppurativa, polyarticular JIA, or uveitis), the patient's disease severity scoring, prior therapy history with conventional agents and any prior biologic exposure, the proposed Humira regimen matched to the FDA label (40 mg SC every other week for RA, PsA, AS; weight-banded loading-and-maintenance schedules for Crohn's adult and pediatric; 160 mg Day 1, 80 mg Day 15, then 40 mg every other week for UC and adult Crohn's induction; 80 mg loading then 40 mg every other week for plaque psoriasis or uveitis; weekly maintenance for HS after induction), the planned response-assessment window, and the monitoring plan. Where biosimilars are locally available, the letter should address why reference Humira (or another specific FDA-approved biosimilar) is being prescribed.

The TB and HBV workup is critical. Humira carries a Boxed Warning for serious infections including tuberculosis, and Pakistan's high TB burden makes the IGRA or PPD documentation a

particularly close-reviewed item in the DRAP file. The letter should document baseline tuberculosis screening with result, hepatitis B serology, and ongoing vigilance for serious infection, malignancy, demyelinating disease, heart failure exacerbation, and lupus-like syndrome. Periodic CBC and clinical follow-up are standard. Reserve Meds supplies a documentation kit pre-formatted to the OIES portal requirements.

Common questions about Humira in Pakistan

What is the HSTCL warning for pediatric IBD? Hepatosplenic T-cell lymphoma (HSTCL) is a rare but serious post-marketing finding in adolescent and young adult patients with inflammatory bowel disease who received TNF-alpha inhibitor therapy, most of whom received concomitant azathioprine or 6-mercaptopurine. The Humira Boxed Warning addresses this signal explicitly. Pediatric IBD prescribing requires careful risk-benefit analysis by the treating gastroenterologist, particularly when combination immunosuppression is considered. Reserve Meds does not direct this clinical decision; the prescribing physician owns the assessment.

Will Adamjee, Jubilee, EFU, or State Life cover this? Coverage for named-patient imports of specialty biologics is uncommon across Pakistani health plans, particularly when the patient is specifying reference Humira over locally available biosimilars. The realistic default is cash-pay. We supply documentation a family or hospital can use to file a claim.

How does Sehat Sahulat interact with a Humira case? The Sehat Sahulat Rs. 1,000,000 per family per year ceiling does not stretch to cover annual Humira drug cost at reference-brand WAC, and the program is generally structured around in-network hospital treatment rather than imported drug procurement. Families who qualify for Sehat Sahulat can still use it for hospitalization and supportive care.

Why ask for reference Humira if Pakistani biosimilars are available? Indian biosimilars (Exemptia, Adfrar) are widely available in Pakistan and several global FDA-approved biosimilars are entering the supply chain. Some patients have stabilized on reference Humira over multiple years, some treating physicians prefer not to substitute mid-course, and some patients have documented intolerance to a specific biosimilar formulation. Reserve Meds coordinates the specific product the prescribing physician has named.

Is there a comparator? Within the TNF-alpha class, prescribers consider infliximab (Remicade and biosimilars), etanercept (Enbrel), certolizumab pegol (Cimzia), and golimumab (Simponi). For specific indications, non-TNF biologics (ustekinumab, vedolizumab, risankizumab, secukinumab, ixekizumab) and JAK inhibitors (upadacitinib, tofacitinib) are alternatives. Class selection is a clinical decision made by the treating physician.

Can Humira be self-administered? Yes, after appropriate prescriber-supervised training. The Humira Pen and prefilled syringe are designed for patient self-injection. The Children's Hospital and Institute of Child Health in Lahore handles training for pediatric weight-banded dosing.

Where Reserve Meds fits in Humira cases

Reserve Meds is a US-based concierge coordinator. We do not replace your physician, DRAP, your hospital pharmacy, or the in-country importer. For Humira specifically, we coordinate US-side sourcing from US-licensed wholesalers (Cencora-AmerisourceBergen, McKesson, Cardinal Health) carrying AbbVie's reference Humira inventory, the documentation kit your physician needs for the OIES portal application including the TB and HBV workup attestations and the biosimilar non-substitution rationale where relevant, validated cold-chain international shipment

with continuous temperature logging through FBR customs at Karachi, Lahore, or Islamabad, and a single named coordinator who stays with your family across every-other-week or weekly resupply cycles. Cold-chain qualification of the destination lane and SKU-level precision (pen vs. syringe, citrate-free vs. citrate-containing) are the operational fundamentals we verify on every Humira case.

Next step

If your physician has specified reference Humira as the right product and the local stocking or biosimilar substitution situation does not match, the path forward is the DRAP Special Permission / Personal Use Import NOC, filed through OIES with Reserve Meds coordinating the US-side sourcing and documentation.

Reserved for you.

About Humira

TNF-alpha inhibitor
Manufacturer: AbbVie
Modality: Subcutaneous prefilled pen or syringe; citrate-free 100 mg/mL standard; cold-chain 2-8°C
Full drug page →

About Pakistan

South Asia, DRAP Personal Use Import NOC, OIES portal
Significant adalimumab biosimilar market; reference Humira reserved when prescribed by brand
Pakistan deep dive →

See also

Humira in Saudi Arabia
Humira in UAE
Humira in India
Simlandi in Pakistan
Stelara in Pakistan

Review and oversight. Content on this page is reviewed by Reserve Meds's clinical and regulatory team. A US-licensed pharmacist reviews every prescription before dispensing. Regulatory posture is informational, not legal advice; case-specific questions route to retained outside counsel. Review methodology ›
Last medically reviewed: 2026-05-12.